Temasek in Strategic Investment in VIVA Biotech

Cleary Gottlieb is representing Temasek in its strategic investment in VIVA Biotech Holdings (VIVA Biotech).

Temasek Holdings, Temasek-owned True Light Capital, and Chinese investment firm HighLight Capital will jointly pay close to $150 million for an approximately 24% stake in VIVA Shanghai, the CRO business entity of VIVA Biotech. Temasek Holdings, True Light Capital, and HighLight Capital will also jointly contribute $60 million to subscribe for convertible bonds of VIVA Biotech.

The transaction signed on June 10, 2023.

Temasek is an investment holding company owned by the government of Singapore.

Founded in 2008, Hong Kong-listed VIVA Biotech (1873.HK) provides one-stop integrated services from early-stage structure-based drug development to commercial drug delivery to global innovative drug R&D companies. VIVA Biotech has achieved outstanding growth in the CRO drug development field, especially in the area of protein structure analysis, where it is a global industry leader. By the end of 2022, VIVA Biotech has provided drug R&D and manufacturing services to 2,076 biotech and pharmaceutical clients worldwide and has invested in 91 biopharmaceutical start-ups.